证券代码：002551 证券简称：尚荣医疗 公告编号：2025-056 深圳市尚荣医疗股份有限公司 关于续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 本次续聘中审众环会计师事务所（特殊普通合伙）（以下简称"中审众环会 计师事务所"）符合财政部、国务院国资委、证监会印发的《国有企业、上市公 司选聘会计师事务所管理办法》（财会〔2023〕4 号）的规定。 深圳市尚荣医疗股份有限公司（以下简称"公司"）于 2025 年 12 月 10 日 召开第八届董事会第十一次临时会议审议通过了《关于续聘会计师事务所的议 案》，公司董事会同意续聘中审众环会计师事务所为公司 2025 年度财务审计及 内部控制审计机构，该事项尚需提交公司股东大会审议，具体情况如下： 一、拟续聘会计师事务所的基本情况 （一）机构信息 服务业务审计报告的注册会计师人数 723 人。 1、基本信息 （1）机构名称：中审众环会计师事务所（特殊普通合伙） （2）成立日期：中审众环始创于 1987 年，是全国首批取得国家批准具有从 事证券、期货相关业务资格及金融业务审计资格 ...

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-055 深圳市尚荣医疗股份有限公司 关于追加使用自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、基本情况 | 投资种类 | 安全性高、流动性强、风险较低的理财产品或进行结构 | | | | | --- | --- | --- | --- | --- | | 投资金额 资金来源 | 不超过人民币 万元) 自有资金 | 50,000 | 万元(含 | 50,000 | 2、特别风险提示 为控制风险，深圳市尚荣医疗股份有限公司（以下简称"公司"）及其全资 子公司和控股子公司使用自有资金进行现金管理时，选择购买安全性高、流动性 强、风险较低的理财产品或进行结构性存款,该产品必须选择具有合法经营资格 的金融机构进行交易，但金融市场受宏观经济的影响较大，公司及其全资子公司 和控股子公司将根据经济形势以及金融市场的变化适时适量的介入，但不排除该 项投资受到市场波动的影响。 3、已履行的审议程序 （1）公司于 2025 年 4 月 26 日召开第八届董事会第二次会议 ...

证券代码：002551 证券简称：尚荣医疗 公告编号：2025-057 深圳市尚荣医疗股份有限公司 关于召开 2025 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市尚荣医疗股份有限公司（以下简称"公司"）第八届董事会第十一次临时 会议审议通过了《关于提请召开公司 2025 年第二次临时股东大会的议案》，会议决 定 2025 年 12 月 29 日召开公司 2025 年第二次临时股东大会，本次股东大会采用现场 投票及网络投票相结合的方式进行。根据《公司章程》的规定，现将召开本次股东大 会的有关事项公告如下： 一、本次股东大会召开的基本情况 1、股东大会届次：2025 年第二次临时股东大会（以下简称"本次股东大会"）。 2、股东大会召集人：董事会。 3、本次会议的召集、召开符合《中华人民共和国公司法》、《深圳证券交易所 股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 12 ...

二、监事会会议审议情况 经与会监事认真审议，形成如下决议： 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-054 深圳市尚荣医疗股份有限公司 第八届监事会第七次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市尚荣医疗股份有限公司（以下简称"公司"）第八届监事会第七次临时 会议，于2025年12月8日以书面、传真及电子邮件的方式发出会议通知和会议议 案，并于2025年12月10日在公司以现场方式召开，本次会议应到监事3名，实到 监事3名，会议由监事会主席黄雪莹女士主持，会议的召集和召开符合《中华人 民共和国公司法》及《公司章程》的规定。 （一）审议通过了《关于公司追加使用自有资金进行现金管理的议案》 为了进一步提高自有资金的使用效率和收益，为公司和股东谋取较好的投资 回报，公司及其全资子公司和控股子公司根据公司经营计划和资金使用情况，在 不影响正常经营活动及风险可控的前提下在原30,000万元(含30,000万元)自有 资金现金管理额度的基础上，追加 20,000 万元(含 20,000 万元)自 ...

一、董事会会议召开情况 证券代码：002551 证券简称：尚荣医疗 公告编号：2025-053 深圳市尚荣医疗股份有限公司 第八届董事会第十一次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 二、董事会会议审议情况 深圳市尚荣医疗股份有限公司（以下简称"公司"或"尚荣医疗"）第八届 董事会第十一次临时会议，于2025年12月8日以书面、传真及电子邮件的方式发 出会议通知和会议议案，并于2025年12月10日在公司以现场加通讯（通讯方式参 加人员为虞熙春、曾江虹、赵俊峰、龙琼）相结合的方式召开，本次会议应参加 表决权董事9名，实际参加表决权董事9名。公司监事均列席了会议。会议由董事 长梁桂秋先生主持，会议的召集和召开符合《中华人民共和国公司法》及《公司 章程》的规定。 经与会董事认真审议，并以记名投票的方式，形成如下决议： （一）审议通过了《关于公司控股子公司向建设银行申请贷款授信额度的议 案》 鉴于原额度已到期，因生产经营需要，公司控股子公司合肥普尔德医疗用品 有限公司（公司持有其股权55%，以下简称"普尔德医疗"）继续向建设银行合 肥滨湖新 ...

Core Viewpoint - The financial performance of Shangrong Medical (002551) shows significant declines in revenue and profit, indicating potential challenges in the medical device industry [2]. Group 1: Stock Performance - As of December 8, 2025, Shangrong Medical's stock closed at 3.92 yuan, with no change in price [1]. - The trading volume was 94,400 hands, with a total transaction value of 37.0863 million yuan [1]. - The net inflow of main funds was 1.7102 million yuan, accounting for 4.61% of the total transaction value [1]. Group 2: Financial Metrics - Shangrong Medical's total market value is 3.314 billion yuan, significantly lower than the industry average of 11.014 billion yuan, ranking 97th out of 124 [2]. - The company reported a net profit of -35.1253 million yuan, a decline of 338.5% year-on-year, ranking 111th in the industry [2]. - The gross profit margin stands at 14.35%, compared to the industry average of 51.22%, ranking 119th [2]. Group 3: Recent Financial Results - For the first three quarters of 2025, the company's main revenue was 754 million yuan, down 24.85% year-on-year [2]. - In Q3 2025, the single-quarter main revenue was 225 million yuan, a decrease of 39.25% year-on-year [2]. - The company's debt ratio is 23.31%, with investment income of 10.2049 million yuan and financial expenses of -3.7891 million yuan [2].

证券之星消息，截至2025年12月3日收盘，尚荣医疗(002551)报收于3.94元，下跌0.25%，换手率 1.84%，成交量11.25万手，成交额4439.66万元。 12月3日的资金流向数据方面，主力资金净流入340.88万元，占总成交额7.68%，游资资金净流出12.3万 元，占总成交额0.28%，散户资金净流出328.58万元，占总成交额7.4%。 近5日资金流向一览见下表： 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-03 | 3.94 -0.25% | 340.88万 | 7.68% | -12.30万 | -0.28% | -328.58万 | -7.40% | | 2025-12-02 | 3.95 0.00% | 66.49万 | 1.59% | -79.83万 | -1.90% | 13.33万 | 0.32% | | 2025-12-0 ...

Core Insights - The stock of Shangrong Medical (002551) closed at 3.95 yuan on December 1, 2025, with an increase of 0.77% and a trading volume of 120,900 hands, resulting in a transaction amount of 47.78 million yuan [1][2]. Financial Performance - For the first three quarters of 2025, Shangrong Medical reported a main revenue of 754 million yuan, a year-on-year decrease of 24.85% [3]. - The net profit attributable to shareholders was -35.13 million yuan, a decline of 338.5% year-on-year [3]. - The third quarter alone saw a main revenue of 225 million yuan, down 39.25% year-on-year, and a net profit of -27.37 million yuan, a drop of 4004.28% year-on-year [3]. Market Position - Shangrong Medical's total market capitalization is 3.34 billion yuan, significantly lower than the industry average of 11.16 billion yuan, ranking 98 out of 124 in the medical device industry [3]. - The company has a negative price-to-earnings ratio of -71.31, compared to the industry average of 59.83, indicating poor profitability [3]. - The gross margin stands at 14.35%, which is substantially below the industry average of 51.22%, ranking 119 out of 124 [3]. Capital Flow Analysis - On December 1, 2025, the net inflow of main funds was 1.38 million yuan, accounting for 2.89% of the total transaction amount, while retail investors saw a net inflow of 1.11 million yuan, making up 2.32% [1][2]. - Over the past five days, the main funds have fluctuated, with notable net inflows and outflows, indicating varying investor sentiment [2].

Group 1: BYD Performance - BYD announced a production of 474,200 new energy vehicles (NEVs) and sales of 480,200 NEVs in November 2025 [1] - Cumulative production for the year reached 4,117,600 units, representing a year-on-year increase of 7.29% [1] - Cumulative sales for the year totaled 4,182,000 units, with a year-on-year growth of 11.30% [1] - In November, BYD exported 131,900 NEVs and installed approximately 27.669 GWh of power batteries and energy storage batteries [1] Group 2: Investment Initiatives - Lushin Venture Capital plans to establish a 400 million yuan investment fund focusing on life sciences, advanced manufacturing, and AI [2] - Chint Electric's wholly-owned subsidiary intends to invest up to 201 million yuan in a green private equity investment fund with a total scale of 700 million yuan [8] Group 3: Corporate Actions - Qianwei Central Kitchen will conduct a shareholder reward activity, offering a product package worth 200 yuan to individual shareholders holding 100 shares or more [3] - Huaxia Happiness plans to use trust beneficiary rights to offset financial debts totaling up to 24 billion yuan as part of its debt restructuring plan [4] - Tailong Pharmaceutical's controlling shareholder is planning a share transfer, leading to a temporary suspension of the company's stock [5] - ST Xianhe has applied to revoke other risk warnings, pending approval from the Shenzhen Stock Exchange [6] - *ST Yuancheng's stock will be delisted due to a market value below 500 million yuan for 20 consecutive trading days [7] Group 4: Sales and Contracts - SAIC Group reported sales of 4,108,000 vehicles from January to November 2025, a year-on-year increase of 16.4% [10] - Geely Automobile's total sales in November reached 310,428 units, marking a 24% increase year-on-year [11] - Far East Holdings' subsidiaries secured contracts worth 2.383 billion yuan in November, positively impacting future earnings [18] - Samsung Medical's subsidiary signed a contract for an annual bidding project in Indonesia worth approximately 160 million yuan [19] - Zhongchao Holdings' subsidiaries recently won contracts totaling 1.318 billion yuan [20] - Changhua Group received a project development notice from a domestic automaker, with an expected total sales amount of approximately 732 million yuan [21]

Fundraising Overview - The company has been approved to publicly issue convertible bonds with a total face value of RMB 750 million, with a term of 6 years [2] - The actual net amount raised after deducting underwriting fees and other expenses is RMB 733.35 million [2][3] Fund Management - The company has established a special account for the management and use of the raised funds, in compliance with relevant regulations [4] - A tripartite supervision agreement has been signed with multiple banks and the sponsor to ensure the funds are used solely for the "high-end medical consumables industrialization project" [4] Fund Usage and Termination - As of the announcement date, all funds from the special accounts have been fully utilized, and the accounts are no longer in use [7] - The company has decided to terminate the "high-end medical consumables industrialization project" and will use the remaining funds of approximately RMB 358.70 million to permanently supplement working capital [6][7]